
0:00
22:37
Dr. Yusaf (PJ) Saleeby shares insights from his practice in 2025 regarding Low Dose Naltrexone (LDN). He discusses patient sensitivity, optimal starting doses, and LDN's efficacy for various conditions including Lyme, cancer, and autoimmune diseases. The conversation also delves into Mast Cell Activation Syndrome (MCAS) and the critical role of informed clinicians in its management.
More episodes from "The LDN Radio Show About Low Dose Naltrexone"



Don't miss an episode of “The LDN Radio Show About Low Dose Naltrexone” and subscribe to it in the GetPodcast app.








